Skip to main content

Press releases | January 8, 2024

Fried Frank acted as counsel to Centerview Partners as financial advisor to Harpoon Therapeutics (Nasdaq: HARP) (“Harpoon”) in its $680 million acquisition by Merck & Co. (NYSE: MRK) (“Merck”). Harpoon is a clinical-stage immunotherapy company developing a novel class of T-cell engagers designed to harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. Merck is an American multinational pharmaceutical company. The transaction is expected to close in the first half of 2024. 

The Fried Frank team was led by partner Roy Tannenbaum.


This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.